Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.34 |
| ▸ | RXRB | P28702 | 4/20 | 0.34 |
| ▸ | RXRG | P48443 | 4/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 3/20 | 0.33 |
| ▸ | PDXK | O00764 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776120 | 0.83 | TDO2 (0.49) | RXRARXRBRXRGNOTUMTDO2 | |
| SCHEMBL5771241 | 0.83 | SIRT2 (0.39) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL5774717 | 0.78 | AHR (0.41) | RXRARXRBRXRGNOTUMMEN1 | |
| SCHEMBL5770454 | 0.78 | RPA1 (0.38) | NOTUMTDO2 | |
| SCHEMBL5770527 | 0.78 | RXRA (0.53) | RXRARXRBRXRG | |
| SCHEMBL5776001 | 0.76 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL5776014 | 0.75 | CYP11B1 (0.38) | NOTUMMEN1KMT2ATDO2 | |
| SCHEMBL5772390 | 0.74 | KMO (0.36) | MEN1KMT2A | |
| SCHEMBL5777173 | 0.74 | NOTUM (0.36) | NOTUMMEN1KMT2ATDO2PTPN1 | |
| SCHEMBL5772173 | 0.74 | TDO2 (0.55) | NOTUMMEN1KMT2ATDO2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | RXRA 445/4885RXRB 494/4885RXRG 503/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | RXRA 462/4885RXRB 550/4885RXRG 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.